GlassScriptPhysician profile
Evie Gray
NPI 1336869437
$1,827.55
in general payments reported to CMS, 2019-2025
21 companies · $738 in 2025
The $738 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $532 · 2024: $558 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $227.66 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $188.95 | 2023-2025 | Lifevest |
| Boston Scientific Corporation | $173.96 | 2023-2024 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $161.70 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.81 | 2023-2025 | Jardiance |
| Medtronic, INC. | $118.66 | 2025 | In.Pact Admiral |
| Amgen INC. | $106.61 | 2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $106.50 | 2023-2025 | Lokelma, Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $91.58 | 2023-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $90.25 | 2024 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $89.79 | 2025 | Camzyos, Eliquis |
| Atricure, INC. | $68.92 | 2023-2025 | Synergy Ablation System |
| Novartis Pharmaceuticals Corporation | $46.77 | 2023-2025 | |
| Pfizer INC. | $36.91 | 2023-2024 | |
| Stryker Corporation | $34.49 | 2025 | Flowtriever |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $33.68 | 2024 | Impella |
| Lexicon Pharmaceuticals, INC. | $30.13 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $23.30 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $16.66 | 2025 | Nexletol |
| Chiesi USA, INC. | $14.48 | 2024 | Cleviprex, Kengreal |
| Novo Nordisk INC | $13.74 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evie Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.